Foundayo Is Here: What Lilly's New GLP-1 Pill Means for You
Lilly's oral GLP-1 — no fasting, any time of day, $149/month. Here's how it compares to the Wegovy pill, injectable GLP-1s, and who it's actually best for.
On April 1, 2026, the FDA approved Foundayo (orforglipron) — Eli Lilly's oral GLP-1 pill for weight loss. It's now the second oral GLP-1 approved for weight management, after the Wegovy pill launched in late 2025. But Foundayo brings something the Wegovy pill doesn't: you can take it at any time of day, with or without food, and without a 30-minute fasting window.
That flexibility might sound like a small thing until you've tried following the Wegovy pill's strict dosing rules every morning for six months. For many patients, Foundayo removes the most frustrating daily friction point in GLP-1 treatment.
What Is Foundayo?
Foundayo is a once-daily pill containing orforglipron, a small-molecule GLP-1 receptor agonist. Unlike injectable semaglutide or tirzepatide (which are peptides), orforglipron was designed from the ground up as an oral drug. It doesn't need the special absorption-enhancing technology that the Wegovy pill requires — which is why it can be taken without food restrictions.
The practical difference: the Wegovy pill must be taken first thing in the morning on an empty stomach, swallowed with no more than 4 ounces of water, and you must wait at least 30 minutes before eating, drinking, or taking other medications. Foundayo has none of those restrictions. Take it with breakfast. Take it before bed. Take it with your other medications. The flexibility is genuinely meaningful for adherence.
How Much Weight Can You Lose?
In the Phase 3 ATTAIN-1 trial, patients on the highest dose of Foundayo lost an average of 27.3 pounds — about 12.4% of their body weight — compared to 2.2 pounds with placebo. That's significant, though it's notably lower than injectable GLP-1 results: the STEP trials showed 15–17% weight loss with injectable Wegovy, and SURMOUNT showed up to 22% with injectable tirzepatide.
The weight loss tradeoff is real, and it's worth understanding: you're getting more convenience in exchange for somewhat lower average weight loss compared to injections. For patients who would never start an injectable — or who've achieved their goal weight on injections and want to switch to a maintenance option — Foundayo fills an important gap.
The ATTAIN-MAINTAIN study added encouraging data: patients who switched from injectable Wegovy to oral Foundayo regained only 0.9 kg on average. This suggests Foundayo can maintain results achieved through injections, which opens a practical pathway — start with injections for maximum weight loss, then transition to a daily pill for long-term maintenance.
Foundayo vs. Wegovy Pill: Head-to-Head
| Feature | Foundayo (orforglipron) | Wegovy Pill (oral semaglutide) |
|---|---|---|
| FDA Approval | April 2026 | December 2025 |
| Drug Type | Small molecule | Peptide + SNAC enhancer |
| Fasting Required | No — any time of day | Yes — empty stomach, 30 min wait |
| Avg Weight Loss | ~12.4% (highest dose) | ~15–17% (adherent patients) |
| Self-Pay Starting | $149/mo | $149/mo |
| Manufacturer | Eli Lilly | Novo Nordisk |
Who Is Foundayo Best For?
Foundayo is worth discussing with your provider if you:
- Take morning medications — thyroid drugs, blood pressure pills, or PPIs that conflict with the Wegovy pill's fasting window
- Drink coffee first thing — the Wegovy pill prohibits anything besides water for 30 minutes; Foundayo has no such restriction
- Have needle anxiety — if self-injection has kept you from starting GLP-1 treatment entirely
- Want a maintenance option — after reaching your goal weight on injectables, a daily pill may be more sustainable long-term
- Travel frequently — pills don't require refrigeration, sharps disposal, or TSA explanations
Who Should Stick With Injectables?
If maximum weight loss is your primary goal, injectable semaglutide and tirzepatide still deliver higher average results (15–22% vs. 12.4%). Patients who are comfortable with weekly injections and are in an active weight loss phase — rather than maintenance — will likely see better outcomes staying with injectables.
Several telehealth providers offer both injectable and oral GLP-1 options, allowing you to work with your provider on the format that fits your stage of treatment.
How to Get Started
Foundayo is available through LillyDirect (Lilly's direct-to-consumer pharmacy) and through telehealth providers and retail pharmacies nationwide. You'll need a prescription from a licensed provider. The process typically involves:
- Complete an online health assessment with a telehealth provider or visit your primary care doctor
- Discuss your weight history, health conditions, and whether oral GLP-1 treatment is appropriate
- If prescribed, fill your prescription through LillyDirect, a retail pharmacy, or a telehealth-partnered pharmacy
- Start at the lowest dose (0.8 mg) and titrate up every 4+ weeks based on tolerability
Foundayo represents a genuine step forward in making GLP-1 treatment more accessible and livable. It's not a replacement for injectable options when maximum weight loss is the goal — but for the millions of people who've been waiting for a convenient, no-fasting pill option, the wait is over.